Media inquiries can be directed to Matt Burns at [email protected] or 518-423-5907.

A collaboration example shows Cellgorithm could shorten a four-month process to under two weeks, illustrating potential speedups.

Syntax Bio unveils Cellgorithm, a CRISPR-based platform described in Science Advances, designed to program and control gene activity in human stem cells.

Cellgorithm holds therapeutic potential for diseases like diabetes, heart failure, Parkinson’s disease, and vision loss by speeding up stem cell therapy development.

Patients stand to gain faster access to stem cell–based therapies as reproducibility improves and clinical research accelerates.

The effort seeks to establish a foundation for programmable gene activity control, aiming for reliability and scalability comparable to software development.

The technology encodes a sequence of gene activations into a single DNA program, ensuring correct activation order with less manual intervention.

The Cellgorithm platform aims to precisely and rapidly direct stem cell differentiation by programming gene activity, reducing manual interventions.

Current differentiation efforts suffer from reproducibility issues, batch variability, and long optimization times that raise costs and hinder scalability.

The related Science Advances publication can be accessed via DOI 10.1126/sciadv.adt1532; the research is experimental and reported in the journal.

The platform targets reproducibility and scalability in regenerative medicine by offering a reliable, programmable approach to differentiation.

Cellgorithm automates the sequence of gene activations to mirror natural development, enabling differentiation in days to weeks instead of months.

Syntax Bio is pursuing collaborations with biopharma to apply Cellgorithm in therapeutic development and drive translation to clinical applications.

Cellgorithm is presented as accelerating differentiation across multiple cell types, addressing reproducibility and scalability challenges.

The key publication is Anupama Puppala et al., detailing programmable multistep CRISPR gene activation via RNA Polymerase III termination, Science Advances (2025), DOI 10.1126/sciadv.adt1532.

Co-founder and CTO Ryan Clarke emphasizes running cell programming like software, with emphasis on temporal control over gene activation.